Information Provided By: 
Fly News Breaks for February 27, 2018
DBVT
Feb 27, 2018 | 07:13 EDT
H.C. Wainwright analyst Andrew Fein says DBV Technologies last night announced positive data from its Phase 2 Miles study evaluating Viaskin Milk against cow milk protein. Solid data in a second indication is a "confidence builder," Fein tells investors in a research note. The data are an important milestone for DBV and epicutaneous immunotherapy, the analyst adds. He believes the "pipeline in a program" thesis, not previously associated with DBV, may be coming into focus. The analyst reiterates a Buy rating on the shares with a $50 price target.
News For DBVT From the Last 2 Days
There are no results for your query DBVT
